S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
RXST · RxSight, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$4.89
+0.02
(+0.41%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$4.89
$4.84
$5.03
52-WEEK RANGE
$4.89
$4.40
$13.22
What's happening
- RXST is up 0.41% today, trading at $4.89. — Live quote
- Volume today (51,629) is well below its 3-month average of 1,001,949. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.29 actual vs. $-0.34 estimated (+13.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 0
Buy 1
Hold 9
Sell 3
Strong sell 2
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
RXST
-53.17%
vs S&P 500
-65.94%
1-YEAR RETURN
RXST
-42.79%
vs S&P 500
-57.35%
6-MONTH RETURN
RXST
-33.88%
3-MONTH RETURN
RXST
-7.05%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.29
Est. $-0.34
BEAT +13.8%
2026-04-26 (Q1 2026)
$-0.38
Est. $-0.29
MISS -32.4%
2026-01-26 (Q4 2025)
$-0.22
Est. $-0.34
BEAT +35.1%
2025-10-26 (Q3 2025)
$-0.24
Est. $-0.39
BEAT +37.9%
Valuation Measures & Ratios
Enterprise Value4$189.7M
Forward P/E5—
PEG Ratio6-0.10
Price / Sales (TTM1)1.59
Price / Book70.76
EV4 / Revenue1.49
EV4 / EBITDA—
Profit Margin-36.80%
Operating Margin-43.20%
Return on Equity (ROE8)-17.35%
Return on Assets (ROA9)-14.71%
Avg Volume (3M)1,001,949
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $200.2M | $257.5M | $367.3M | $527.5M | $1.03B |
| P/E | -4.04 | -5.64 | -10.17 | -16.29 | -34.80 |
| Price/Book | 0.76 | 0.96 | 1.33 | 1.90 | 3.70 |
| EV/EBITDA | -3.44 | -4.66 | -7.94 | — | — |
| ROE | -18.83% | -17.09% | -13.09% | -11.65% | -10.64% |
| ROA | -14.06% | -15.03% | -11.71% | -10.48% | -9.49% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short4,087,921
Change from Prior Settlement+2.82%
% of Float—
Days to Cover (Short Ratio)4.63
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 0.3% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-09-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -36.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -42.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on RXST
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $33.7M | — | — | $33.6M | — | — | — | — |
| Gross profit | — | $23.5M | $24.2M | $25.2M | $28.3M | $25.2M | $24.2M | $20.7M |
| Operating income | -$13.8M | -$17.8M | -$12.2M | -$14.0M | -$10.7M | -$9.2M | -$8.3M | -$10.7M |
| Net income | -$12.1M | -$15.9M | -$9.8M | -$11.8M | -$8.2M | -$6.3M | -$6.1M | -$9.1M |
| EPS (diluted) | $-0.29 | $-0.38 | $-0.24 | $-0.29 | $-0.20 | $-0.16 | $-0.16 | $-0.25 |
| EPS (basic) | $-0.29 | $-0.38 | $-0.24 | $-0.29 | $-0.20 | $-0.16 | $-0.16 | $-0.25 |
| Operating margin | -$41 | — | — | -$42 | — | — | — | — |
| Net margin | -$36 | — | — | -$35 | — | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $352.7M | $304.0M | $311.8M | $308.5M | $309.0M | $313.0M | $318.6M | $310.5M |
| Total liabilities | $89.4M | $36.7M | $36.1M | $32.6M | $31.0M | $33.7M | $37.3M | $33.2M |
| Stockholders' equity | $263.3M | $267.3M | $275.7M | $276.0M | $278.0M | $279.3M | $281.2M | $277.3M |
| Total current assets | $327.4M | $279.2M | $287.5M | $283.9M | $283.9M | $288.4M | $293.8M | $286.8M |
| Total current liabilities | $80.4M | $27.4M | $26.3M | $22.3M | $20.4M | $22.7M | $25.9M | $22.6M |
| Cash & equivalents | $13.4M | $17.6M | $19.9M | $29.6M | $40.4M | $28.0M | $16.7M | $16.7M |
| Marketable securities (current) | $195.4M | $200.3M | $208.2M | $197.9M | $187.1M | $201.3M | $220.5M | $220.4M |
| Accounts receivable | $18.5M | $22.4M | $23.4M | $24.2M | $28.1M | $31.0M | $30.1M | $25.4M |
| Inventory | $37.1M | $34.9M | $31.6M | $28.9M | $25.1M | $23.6M | $22.0M | $21.7M |
| Property, plant & equipment | $14.0M | $13.2M | $13.1M | $13.1M | $13.3M | $12.6M | $12.4M | $12.2M |
| Other non-current assets | $1.0M | $1.0M | $590.0K | $536.0K | $542.0K | $401.0K | $360.0K | $213.0K |
| Accounts payable | $6.3M | $7.1M | $5.3M | $3.4M | $3.3M | $7.1M | $4.5M | $4.6M |
| Accrued liabilities | — | — | $19.8M | — | — | — | $20.4M | — |
| Deferred revenue (current) | $6.9M | — | $3.3M | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $41.0K | $41.0K | $41.0K | $41.0K | $41.0K | $41.0K | $40.0K | $40.0K |
| Retained earnings | -$689.0M | -$676.9M | -$661.0M | -$651.9M | -$642.1M | -$630.3M | -$622.1M | -$616.2M |
| Accumulated other comprehensive income (loss) | -$59.0K | -$67.0K | $53.0K | $60.0K | -$117.0K | $15.0K | $166.0K | $521.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.5M | -$10.9M | -$1.1M | -$1.2M | -$4.4M | -$8.8M | -$4.3M | $650.0K |
| Investing cash flow | $4.7M | $8.8M | -$9.6M | -$9.0M | $14.7M | $20.9M | $1.3M | -$9.3M |
| Financing cash flow | $662.0K | -$336.0K | $1.1M | -$530.0K | $2.1M | -$735.0K | $3.0M | $878.0K |
| Free cash flow | -$11.5M | -$11.7M | -$2.3M | -$1.8M | -$5.9M | -$9.4M | -$5.1M | -$453.0K |
| Capital expenditures | $2.0M | $759.0K | $1.1M | $581.0K | $1.5M | $575.0K | $847.0K | $1.1M |
| Depreciation & amortization | $999.0K | $834.0K | $851.0K | $854.0K | $785.0K | $776.0K | $515.0K | $1.1M |
| Share-based compensation | $7.5M | $7.9M | $7.8M | $8.1M | $8.5M | $7.1M | $7.3M | $6.6M |
| Deferred income taxes | — | — | $6.5M | — | — | — | $19.1M | — |
| Change in accounts receivable | -$3.7M | -$936.0K | -$788.0K | -$3.9M | -$2.9M | $928.0K | $4.7M | -$320.0K |
| Change in inventory | $3.4M | $3.4M | $3.2M | $4.0M | $2.7M | $1.6M | $408.0K | $2.4M |
| Change in accounts payable | -$631.0K | $1.6M | $2.2M | -$86.0K | -$3.7M | $2.2M | $116.0K | $41.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Gross profit | $103.0M | $98.9M | $53.8M | $21.3M | $4.5M |
| Operating income | -$48.2M | -$36.9M | -$50.1M | -$63.3M | -$52.8M |
| Net income | -$38.9M | -$27.5M | -$48.6M | -$66.8M | -$48.7M |
| EPS (diluted) | $-0.95 | $-0.71 | $-1.41 | $-2.41 | $-3.57 |
| EPS (basic) | $-0.95 | $-0.71 | $-1.41 | $-2.41 | $-3.57 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $311.8M | $318.6M | $182.6M | $150.2M | $192.7M |
| Total liabilities | $36.1M | $37.3M | $22.2M | $60.3M | $54.5M |
| Stockholders' equity | $275.7M | $281.2M | $160.4M | $89.9M | $138.2M |
| Total current assets | $287.5M | $293.8M | $168.4M | $134.6M | $176.3M |
| Total current liabilities | $26.3M | $25.9M | $20.9M | $17.2M | $11.1M |
| Cash & equivalents | $19.9M | $16.7M | $9.7M | $11.8M | $24.4M |
| Marketable securities (current) | $208.2M | $220.5M | $117.5M | $94.0M | $135.0M |
| Accounts receivable | $23.4M | $30.1M | $20.3M | $11.0M | $4.9M |
| Inventory | $31.6M | $22.0M | $17.4M | $14.8M | $8.0M |
| Property, plant & equipment | $13.1M | $12.4M | $10.8M | $10.1M | $11.2M |
| Other non-current assets | $590.0K | $360.0K | $147.0K | $767.0K | $114.0K |
| Accounts payable | $5.3M | $4.5M | $3.9M | $2.6M | $1.7M |
| Accrued liabilities | $19.8M | $20.4M | $15.2M | $12.7M | $7.9M |
| Long-term debt | — | — | $0 | $40.2M | $39.8M |
| Common stock & paid-in capital | $41.0K | $40.0K | $36.0K | $28.0K | $27.0K |
| Retained earnings | -$661.0M | -$622.1M | -$594.6M | -$546.0M | -$479.3M |
| Accumulated other comprehensive income (loss) | $53.0K | $166.0K | -$5.0K | -$95.0K | -$20.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$15.5M | -$16.9M | -$41.6M | -$58.9M | -$44.7M |
| Investing cash flow | $16.9M | -$99.3M | -$22.1M | $40.0M | -$81.9M |
| Financing cash flow | $1.9M | $123.3M | $61.5M | $6.3M | $137.3M |
| Free cash flow | -$19.3M | -$22.4M | -$46.4M | -$61.2M | -$46.6M |
| Capital expenditures | $3.8M | $5.4M | $4.8M | $2.4M | $1.9M |
| Depreciation & amortization | $3.3M | $3.6M | $4.1M | $3.9M | $4.0M |
| Share-based compensation | $31.6M | $24.6M | $15.7M | $11.4M | $7.6M |
| Deferred income taxes | $6.5M | $19.1M | $12.8M | $14.9M | -$13.2M |
| Change in accounts receivable | -$6.7M | $9.8M | $9.3M | $6.1M | $2.0M |
| Change in inventory | $11.5M | $5.0M | $2.7M | $7.6M | $2.1M |
| Change in accounts payable | $627.0K | $946.0K | $1.2M | $635.0K | $555.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding RXST as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-28 to 2026-09-15
Recent transactions
- Insiders have net sold 16,947 shares over the last 182 days, across 0 purchases and 4 sales.
- Most recent: Weinberg Eric (See remarks) — Option exercise of 35,168 shares on 2026-09-15.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)16,947 sh(4 txns)
Net Shares-16,947
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Weinberg Eric | See remarks | Option exercise | 2026-09-15 | 35,168 |
| Kurtz Ronald M MD | Chief Medical Officer | Open market sale | 2026-09-02 | 5,100 |
| Wilterding Mark | Chief Financial Officer | Open market sale | 2026-09-02 | 7,765 |
| Goldshleger Ilya | Chief Operating Officer | Open market sale | 2026-09-02 | 2,041 |
| Warner Robert Keith | Reporting person | Grant / award | 2026-06-17 | 37,037 |
| PALMISANO ROBERT J | Reporting person | Grant / award | 2026-06-17 | 37,037 |
| Maniar Shweta | Reporting person | Grant / award | 2026-06-17 | 37,037 |
| Fountain Tamara | Reporting person | Grant / award | 2026-06-17 | 37,037 |
| LINK WILLIAM J PHD | Reporting person | Grant / award | 2026-06-17 | 37,037 |
| Corley Jesse Anderson | Reporting person | Grant / award | 2026-06-17 | 37,037 |
| COHEN RAYMOND W | Reporting person | Grant / award | 2026-06-17 | 30,864 |
| Tammenoms Bakker Juliet | Reporting person | Grant / award | 2026-06-17 | 37,037 |
| Andrews Julie | Reporting person | Grant / award | 2026-06-17 | 37,037 |
| Gaines Scott | Chief Customer Officer | Option exercise | 2026-02-28 | 6,261 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-15 | Weinberg Eric | See remarks | Option exercise | 35,168 | $4.34 |
| 2026-09-02 | Kurtz Ronald M MD | Chief Medical Officer | Open market sale | 5,100 | $6.96 |
| 2026-09-02 | Wilterding Mark | Chief Financial Officer | Open market sale | 7,765 | $6.96 |
| 2026-09-02 | Goldshleger Ilya | Chief Operating Officer | Open market sale | 2,041 | $6.96 |
| 2026-09-02 | Weinberg Eric | See remarks | Open market sale | 2,041 | $6.96 |
| 2026-08-31 | Kurtz Ronald M MD | Chief Medical Officer | Option exercise | 13,425 | — |
| 2026-08-31 | Wilterding Mark | Chief Financial Officer | Option exercise | 20,441 | — |
| 2026-08-31 | Goldshleger Ilya | Chief Operating Officer | Option exercise | 5,370 | — |
| 2026-08-31 | Weinberg Eric | See remarks | Option exercise | 5,370 | — |
| 2026-06-17 | Warner Robert Keith | Reporting person | Grant / award | 37,037 | — |
| 2026-06-17 | PALMISANO ROBERT J | Reporting person | Grant / award | 37,037 | — |
| 2026-06-17 | Maniar Shweta | Reporting person | Grant / award | 37,037 | — |
| 2026-06-17 | Fountain Tamara | Reporting person | Grant / award | 37,037 | — |
| 2026-06-17 | LINK WILLIAM J PHD | Reporting person | Grant / award | 37,037 | — |
| 2026-06-17 | Corley Jesse Anderson | Reporting person | Grant / award | 37,037 | — |
| 2026-06-17 | COHEN RAYMOND W | Reporting person | Grant / award | 30,864 | — |
| 2026-06-17 | Tammenoms Bakker Juliet | Reporting person | Grant / award | 37,037 | — |
| 2026-06-17 | Andrews Julie | Reporting person | Grant / award | 37,037 | — |
| 2026-04-17 | Goldshleger Ilya | Chief Operating Officer | Option exercise | 12,489 | $4.13 |
| 2026-02-28 | Wilterding Mark | Chief Financial Officer | Option exercise | 20,441 | — |
| 2026-02-28 | Wilterding Mark | Chief Financial Officer | Tax withholding | 8,068 | $7.61 |
| 2026-02-28 | Gaines Scott | Chief Customer Officer | Option exercise | 6,261 | — |
| 2026-02-28 | Gaines Scott | Chief Customer Officer | Tax withholding | 2,580 | $7.61 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:07 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-16 | 4 | 2026-09-15 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-05 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-05 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-05 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-05 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-07-24 | 4 | 2026-07-24 | View on SEC.gov → |
Recent news
Headlines about RXST (RxSight, Inc.). Links open the publisher — we don’t host full articles.
-
RxSight Inc. Q3FY26 Results: Earnings call set for November 3, 2026
scanx.trade · 2026-10-20 -
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
Yahoo · 2026-10-20 -
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
Yahoo · 2026-10-19 -
A sales leader with over 30 years in eye care joins RxSight.
Stock Titan · 2026-10-19 -
RxSight announces Alcon lens deal as analysts target RxSight stock at USD 8.17 - ad-hoc-news.de
ad-hoc-news.de · 2026-10-16 -
RxSight's Utilization-Growth Upside Faces Structural, Competitive Headwinds, BofA Says
Yahoo Finance · 2026-09-23 -
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
Yahoo Finance · 2026-08-26 -
RxSight (RXST) Q2 2026 Earnings Call Transcript
Yahoo Finance · 2026-08-12
No headlines in this category right now — try “All”.